$OMDA

Shao Wei-Li sold $79K of OMDA

Shao Wei-Li (President) sold 4,589 shares of Omada Health, Inc. (OMDA) at $17.24 on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shao Wei-Li
Published Jun 16, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure provides transparency on insider ownership changes but does not, by itself, indicate a change in company fundamentals.

02

Market read

Traders may monitor for insider-selling trends, but the 10b5-1 framing and lack of new fundamentals suggest limited immediate trading impact.

03

What to watch

The article doesn’t state whether other insiders bought/sold, whether the sale was part of a larger multi-tranche program, or whether there were concurrent company-specific catalysts.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-12

Background

This is an SEC Form 4 insider transaction disclosure for an officer of Omada Health.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health President Shao Wei-Li sold 4,589 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be second-order sentiment rather than a fundamental catalyst.

Evidence & confidence

The filing is a standard officer sale with a stated 10b5-1 pre-arranged plan and no accompanying operational/regulatory/financial change in the text.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of near-term valuation risk; traders may still fade short-term sentiment.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Shao Wei-Li

    President who executed the open-market sale under a pre-arranged 10b5-1 plan.

Related articles

$OMDAHigh

Omada Health, Inc. (OMDA): Results of Operations and Financial Condition

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 q2fy26pressrelease.htm EX-99 Document Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Becom